NCT02623751View on ClinicalTrials.gov

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Breast Cancer
Interventions
DRUG

KHK2375

"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."

DRUG

Exemestane

"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."

Trial Locations (3)

Unknown

Chikusa-ku

Chuo-ku

Chuo-ku

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT02623751 - Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer | Biotech Hunter | Biotech Hunter